A dental look at the autistic patient through orofacial pain

Acta Odontologica Scandinavica

Volumn 69, Issue 4, 2011, Pages 193-200

  Zeidán Chuliá, Fares ^a,b   Gursoy, Ulvi K ^c   Könönen, Eija ^c   Gottfried, Carmem ^a,b  

^a Institute of Basic Health Sciences   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^c UNIVERSITY OF TURKU   (Finland)

Author keywords

Amalgam fillings; autism; behavioral symptoms; dental intervention; oral health

Indexed keywords

DENTAL ALLOY;

AUTISM; CHILD; DENTAL CARE; FACE PAIN; HUMAN; MENTAL DEFICIENCY; MOTOR DYSFUNCTION; NEURALGIA; PATHOPHYSIOLOGY; PSYCHOLOGICAL ASPECT; REVIEW;

AUTISTIC DISORDER; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; DENTAL AMALGAM; DENTAL CARE FOR DISABLED; FACIAL PAIN; HUMANS; MENTAL RETARDATION; MOVEMENT DISORDERS; NEURALGIA;

EID: 79959498874     PISSN: 00016357     EISSN: 15023850     Source Type: Journal    
DOI: 10.3109/00016357.2010.549505     Document Type: Review

References (67)

1. Gadia CA, Tuchman R, Rotta NT. Autism and pervasive developmental disorders. J Pediatr (Rio J) 2004;80:S83-94 (in Portugeuse).
2. Casanova MF. The neuropathology of autism. Brain Pathol 2007;17:422-33. (Pubitemid 47537606)
3. Rapin I, Tuchman RF. Autism: definition, neurobiology, screening, diagnosis. Pediatr Clin North Am 2008;55: 1129-46, viii.
4. Zimmermann M. Pathobiology of neuropathic pain. Eur J Pharmacol 2001;429:23-37. (Pubitemid 33043979)
5. Scully C, Shotts R. ABC of oral health. Mouth ulcers and other causes oforofacial soreness and pain. BMJ 2000;321: 162-5. (Pubitemid 30447013)
6. Siqueira JT, Lin HC, Nasri C, Siqueira SR, Teixeira MJ, Heir G, et al. Clinical study of patients with persistent oro-facial pain. Arq Neuropsiquiatr 2004;62:988-96. (Pubitemid 40013096)
7. Sarlani E, Balciunas BA, Grace EG. Orofacial pain-Part I: Assessment and management of musculoskeletal and neuro-pathic causes. AACN Clin Issues 2005;16:333-46.
8. Sarlani E, Balciunas BA, Grace EG. Orofacial Pain-Part II: Assessment and management of vascular, neurovascular, idiopathic, secondary, and psychogenic causes. AACN Clin Issues 2005;16:347-58.
9. Spencer CJ, Gremillion HA. Neuropathic orofacial pain: proposed mechanisms, diagnosis, and treatment considera-tions. Dent Clin North Am 2007;51:209-24. (Pubitemid 44917955)
10. Graff-Radford SB. Facial pain. Curr Opin Neurol 2000;13: 291-6. (Pubitemid 30406537)
11. Haraldstad K, Sorum R, Eide H, Natvig GK, Helseth S. Pain in children and adolescents: prevalence, impact on daily life, and parents' perception, a school survey. Scand J Caring Sci 2010 Apr 13 [Epub ahead ofprint].
12. Sessle BJ. Why are the diagnosis and management oforofacial pain so challenging? J Can Dent Assoc 2009;75:275-7.
13. Friedlander AH, Yagiela JA, Paterno VI, Mahler ME. The pathophysiology, medical management, and dental impli-cations of autism. J Calif Dent Assoc 2003;31:681-2, 684, 684-91.
14. Friedlander AH, Yagiela JA, Paterno VI, Mahler ME. The neuropathology, medical management and dental implica-tions ofautism. J Am Dent Assoc 2006;137:1517-27. (Pubitemid 44877766)
15. Clark GT, Ram S. Four oral motor disorders: bruxism, dystonia, dyskinesia and drug-induced dystonic extrapyrami-dal reactions. Dent Clin North Am 2007;51:225-43, viii-ix.
16. Muthu MS, Prathibha KM. Management of a child with autism and severe bruxism: a case report. J Indian Soc Pedod Prev Dent 2008;26:82-4.
17. Lavigne GJ, Khoury S, Abe S, Yamaguchi T, Raphael K. Bruxism physiology and pathology: an overview for clinicians. J Oral Rehabil 2008;35:476-94.
18. Svensson P, Jadidi F, Arima T, Baad-Hansen L, Sessle BJ. Relationships between craniofacial pain and bruxism. J Oral Rehabil 2008;35:524-47.
19. Tolosa E, Marti MJ. Blepharospasm-oromandibular dystonia syndrome (Meige's syndrome): clinical aspects. Adv Neurol 1988;49:73-84.
20. Klawans HL, Tanner CM, Goetz CG. Epidemiology and pathophysiology of tardive dyskinesias. Adv Neurol 1988; 49:185-97.
21. Blanchet PJ, Rompre PH, Lavigne GJ, Lamarche C. Oral dyskinesia: a clinical overview. Int J Prosthodont 2005; 18:10-9. (Pubitemid 40203328)
22. Casey DE. Pathophysiology of antipsychotic drug-induced movement disorders. J Clin Psychiatry 2004;65(Suppl 9): 25-8.
23. Blanchet PJ, Popovici R, Guitard F, Rompre PH, Lamarche C, Lavigne GJ. Pain and denture condition in edentulous orodyskinesia: comparisons with tardive dyskine-sia and control subjects. Mov Disord 2008;23:1837-42.
24. Lee KH. Oromandibular dystonia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007;104:491-6.
25. Carlson CD, Cavazzoni PA, Berg PH, Wei H, Beasley CM, Kane JM. An integrated analysis ofacute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine. J Clin Psychiatry 2003; 64:898-906. (Pubitemid 37022755)
26. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009;373:31-41.
27. Scott LJ, Dhillon S. Risperidone: a review of its use in the treatment of irritability associated with autistic disorder in children and adolescents. Paediatr Drugs 2007;9:343-54. (Pubitemid 47557115)
28. Woolf CJ. Pain: moving from symptom control toward mechanism-specific pharmacologic management. Ann Intern Med 2004;140:441-51. (Pubitemid 38327332)
29. Classification of chronic pain. Descriptions of chronic pain syndromes and definitions of pain terms. Prepared by the International Association for the Study of Pain, Subcommittee on Taxonomy. Pain Suppl 1986;3:S1-226.
30. Ren K, Dubner R. Neuron-glia crosstalk gets serious: role in pain hypersensitivity. Curr Opin Anaesthesiol 2008;21:570-9.
31. Okada-Ogawa A, Suzuki I, Sessle BJ, Chiang CY, Salter MW, Dostrovsky JO, et al. Astroglia in medullary dorsal horn (trigeminal spinal subnucleus caudalis) are involved in tri-geminal neuropathic pain mechanisms. J Neurosci 2009;29: 11161-71.
32. Guo W, Wang H, Watanabe M, Shimizu K, Zou S, LaGraize SC, et al. Glial-cytokine-neuronal interactions underlying the mechanisms of persistent pain. J Neurosci 2007;27:6006-18. (Pubitemid 46849761)
33. Avivi-Arber L, Lee JC, Sessle BJ. Effects of incisor extraction on jaw and tongue motor representations within face sensorimotor cortex of adult rats. J Comp Neurol 2010; 518:1030-45.
34. Suter MR, Wen YR, Decosterd I, Ji RR. Do glial cells control pain? Neuron Glia Biol 2007;3:255-68. (Pubitemid 351594231)
35. Nelson KB, Grether JK, Croen LA, Dambrosia JM, Dickens BF, Jelliffe LL, et al. Neuropeptides and neurotro-phins in neonatal blood of children with autism or mental retardation. Ann Neurol 2001;49:597-606. (Pubitemid 32429787)
36. Miyazaki K, Narita N, Sakuta R, Miyahara T, Naruse H, Okado N, et al. Serum neurotrophin concentrations in autism and mental retardation: a pilot study. Brain Dev 2004;26:292-5. (Pubitemid 38692430)
37. Pardo CA, Eberhart CG. The neurobiology of autism. Brain Pathol 2007;17:434-47. (Pubitemid 47537607)
38. Zakrzewska JM. Facial pain: neurological and non-neurological. J Neurol Neurosurg Psychiatry 2002;72 (Suppl 2):ii27-ii32.
39. Scully C, Porter S. Orofacial disease: update for the clinical team: 9. Orofacial pain. Dent Update 1999;26:410-17.
40. Benoeliel R, Pertes RA, Eliav E. Orofacial pain: Current therapy in pain. In: Smith H, editor. Saunders Elsevier: Philadelphia, PA; 2009. p. 121.
41. Ricketts DN, Pitts NB. Traditional operative treatment options. Monogr Oral Sci 2009;21:164-73.
42. Palkovicova L, Ursinyova M, Masanova V, Yu Z, Hertz-Picciotto I. Maternal amalgam dental fillings as the source ofmercury exposure in developing fetus and newborn. J Expo Sci Environ Epidemiol 2008;18:326-31. (Pubitemid 351556083)
43. Guzzi G, Grandi M, Cattaneo C. Should amalgam fillings be removed? Lancet 2002;360:2081.
44. Pizzichini M, Fonzi M, Giannerini F, Mencarelli M, Gasparoni A, Rocchi G, et al. Influence of amalgam fillings on Hg levels and total antioxidant activity in plasma ofhealthy donors. Sci Total Environ 2003;301:43-50. (Pubitemid 35463213)
45. Weiner JA, Nylander M. The relationship between mercury concentration in human organs and different predictor variables. Sci Total Environ 1993;138:101-15.
46. Mutter J, Naumann J, Guethlin C. Comments on the article "the toxicology of mercury and its chemical compounds" by Clarkson and Magos (2006). Crit Rev Toxicol 2007;37: 537-49. (Pubitemid 47174575)
47. Ask K, Akesson A, Berglund M, Vahter M. Inorganic mercury and methylmercury in placentas of Swedish women. Environ Health Perspect 2002;110:523-6. (Pubitemid 34546514)
48. Drasch G, Schupp I, Hofl H, Reinke R, Roider G. Mercury burden of human fetal and infant tissues. Eur J Pediatr 1994; 153:607-10. (Pubitemid 24240003)
49. Luglie PF, Campus G, Chessa G, Spano G, Capobianco G, Fadda GM, et al. Effect of amalgam fillings on the mercury concentration in human amniotic fluid. Arch Gynecol Obstet 2005;271:138-42. (Pubitemid 40476245)
50. Vimy MJ, Hooper DE, King WW, Lorscheider FL. Mercury from maternal "silver" tooth fillings in sheep and human breast milk. A source of neonatal exposure. Biol Trace Elem Res 1997;56:143-52. (Pubitemid 27215532)
51. NelsonBK. Evidence for behavior altera to genicity in humans. J Appl Toxicol 1991;11:33-7
52. National Research Council Committee on the toxicology of methymercury. Toxicological effects of methylmercury. Washington D.C.: Nacional Academy Press; 2000.
53. Mutter J, Naumann J, Schneider R, Walach H, Haley B. Mercury and autism: accelerating evidence? Neuro Endocrinol Lett 2005;26:439-46. (Pubitemid 43013711)
54. Bernard S, Enayati A, Roger H, Binstock T, Redwood L. The role ofmercury in the pathogenesis ofautism. Mol Psychiatry 2002;7(Suppl 2):S42-3.
55. Geier DA, King PG, Sykes LK, Geier MR. A comprehensive review ofmercury provoked autism. Indian J Med Res 2008; 128:383-411.
56. Geier DA, Kern JK, Geier MR. A prospective study of prenatal mercury exposure from maternal dental amalgams and autism severity. Acta Neurobiol Exp (Wars) 2009;69: 189-97.
57. Palmer RF, Blanchard S, Wood R. Proximity to point sources of environmental mercury release as a predictor of autism prevalence. Health Place 2009;15:18-24.
58. Clarkson TW, Magos L. The toxicology of mercury and its chemical compounds. Crit Rev Toxicol 2006;36: 609-62. (Pubitemid 44396731)
59. Echeverria D, Woods JS, Heyer NJ, Rohlman D, Farin FM, Li T, et al. The association between a genetic polymorphism of coproporphyrinogen oxidase, dental mercury exposure and neurobehavioral response in humans. Neurotoxicol Teratol 2006;28:39-48. (Pubitemid 43254882)
60. Sugita M. The biological half-time of heavy metals. The existence of a third, "slowest" component. Int Arch Occup Environ Health 1978;41:25-40. (Pubitemid 8264708)
61. Loo CY, Graham RM, Hughes CV. The caries experience and behavior of dental patients with autism spectrum disorder. J Am Dent Assoc 2008;139:1518-24.
62. Rada RE. Controversial issues in treating the dental patient with autism. J Am Dent Assoc 2010;141:947-53.
63. Rogers SJ, Ozonoff S. Annotation: what do we know about sensory dysfunction in autism? A critical review of the empir-ical evidence. J Child Psychol Psychiatry 2005;46:1255-68.
64. Tuchman R. Treatment of seizure disorders and EEG abnor-malities in children with autism spectrum disorders. J Autism Dev Disord 2000;30:485-9.
65. Malone RP, Waheed A. The role of antipsychotics in the management of behavioural symptoms in children and ado-lescents with autism. Drugs 2009;69:535-48.
66. Friedlander AH, Yagiela JA, Mahler ME, Rubin R. The pathophysiology, medical management and dental implica-tions of adult attention-deficit/ hyperactivity disorder. J Am Dent Assoc 2007;138:475-82.
67. Robbins MR. Dental management of special needs patients who have epilepsy. Dent Clin North Am 2009;53:295-309, ix.